BioSpace News Archive

Gladstone researchers show that ApoE4 from neurons plays a much more critical role in the disease than previously thought

Omega Laboratories, a leading provider of laboratory testing solutions, is proud to announce a new partnership with Life Diagnostics to open state-of-the-art drugs of abuse testing laboratory in the United Arab Emirates.

Brain research and advocacy non-profit Cohen Veterans Bioscience (CVB) announces the publication of results from its data sciences research program.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2022 on Monday, February 27, 2023, after market close.

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023, at 1:00 p.m. ET.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2022 and provided an update on its recent corporate activities and outlook.

Novavax, Inc., a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, will participate in two upcoming conferences.

Exact Sciences Corp. announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.